about
The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathiesUse of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)Implementing a statin switching programme in primary care: patients' views and experiences.Switching statins in Norway after new reimbursement policy: a nationwide prescription study.Which interventions offer best value for money in primary prevention of cardiovascular disease?Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.Has cost inhibited the uptake of more potent statins in England?Switching statins: NICE tool overestimates benefits of statins.Switching statins: cost of simvastatin is overestimated.Switching statins: how to do it without tears and to benefit the NHS.How much will Herceptin really cost? The money is already there.A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.Impact of two different health systems on the burden of type 2 diabetes.Using primary care prescribing databases to determine drug switching and continuation of care.Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?New mechanism to identify cost savings in English NHS prescribing: minimising 'price per unit', a cross-sectional study.The Office of Fair Trading report: a prescription for value-based drug pricing.Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
P2860
Q33350185-16F683EB-9297-470D-BB34-BCF46BEC06EAQ33664087-3DCCAD1C-CA8B-4D09-A8E3-4895D2E5DA52Q35605494-91EEC736-E0C7-4E4D-A886-F146664A3BF9Q36087995-973B710A-74C6-4B8D-BEFB-BD9F2324AB4CQ36102629-DDCBCD7C-7F76-45A1-BA83-F88F08FC0413Q36109666-675605AB-BD93-40C6-B2F0-E0D93636A967Q36388093-12FE891D-FE71-4252-99F0-0FC467A0331DQ37471385-6DCB4874-8741-4CAA-8DC7-7C2709329B68Q38726224-2E5BF862-AC51-4E7A-96ED-16AA29AE2854Q42399485-CFA95722-CF35-4EFB-BD3F-2BC1DA941CB5Q42399489-24CCFA71-84DF-4F6B-89C3-74C2BF4CD956Q42399625-40304EF2-E393-4B51-B93A-34BF55D1AAEFQ43131484-AD5FBECE-D312-4402-BC7A-CAFB0F0CB390Q43278216-3EB28C07-466C-44CB-9AB9-87D539EC1A75Q43948677-62602F4C-5A4A-4F0C-9A9C-424354C88CB0Q44228643-83AEFDB6-84BC-4CF7-A569-D9715373551DQ44509977-75F7A778-60B6-40BD-AD81-D54DE8F670FBQ45210049-BB80EF5C-52C6-4907-9A95-75691EF9F427Q45324181-2FDB39A2-FD81-432F-A358-4AD9F09098D8Q50035942-DF7CD422-8964-479C-825C-DFCB0A1B6385Q50686440-AC1CBD66-664A-4638-97F4-73412E50556FQ51297152-F3D6E08F-D5BE-49C5-8731-3238A92AAA0C
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Switching statins.
@en
Switching statins.
@nl
type
label
Switching statins.
@en
Switching statins.
@nl
prefLabel
Switching statins.
@en
Switching statins.
@nl
P2860
P1433
P1476
Switching statins.
@en
P2093
James C Moon
Richard G Bogle
P2860
P304
P356
10.1136/BMJ.332.7554.1344
P407
P577
2006-06-01T00:00:00Z